ESC 365 - Activation of beta3-AR with mirabegron in hypertrophic cardiomyopathy: the BETA3LVH trial.

ESC Professional Premium Access

Activation of beta3-AR with mirabegron in hypertrophic cardiomyopathy: the BETA3LVH trial.

Session: Beta3 adrenergic agonists in the clinic: the end of the beginning

Topic: Pharmacology and Pharmacotherapy

Speaker: Associate Professor R. Wachter (Leipzig, DE)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Associate Professor Rolf Wachter

University hospital Leipzig AoR, Leipzig (Germany)

8 presentations

0 follower

3 more presentations in this session

Beta3 adrenergic receptors: where, and what for?

Speaker: Professor J. Balligand (Brussels, BE)

Mirabegron in patients with pulmonary hypertension: the SPHERE-HF trial.

Speaker: Doctor A. Garcia-Alvarez (Barcelona, ES)

Mirabegron in peripheral vascular disease: the STAR-PAD trial.

Speaker: Doctor M. Gray (Sydney, AU)

Access the full session

Beta3 adrenergic agonists in the clinic: the end of the beginning

Speakers: Associate Professor R. Wachter, Professor J. Balligand, Doctor A. Garcia-Alvarez, Doctor M. Gray

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources